The Chemical Distribution Expertise Since 1991

Learn more

Research Tax Credit Approved Since 2019

"This Research Tax Credit approval is a real recognition of SOCOSUR's ability to support the R&D and innovation issues of its customers" comments Matthieu CHAREYRE, President.

Learn more

Bringing You the Best GDP Expertise

Bringing you the best expertise Discover our missions

Learn more

Where GMPs are No Longer an Option Since 2007

Socosur Chem. has a solid track record of GDP inspections by European regulatory bodies, as we are the 3rd GDP approved company ever in France.

Learn more

API Product Focus Cyclosporin

Cyclosporine is a drug used for several types of diseases: for the preventive treatment of organ graft rejection during transplantation as well as for the treatment of certain inflammatory diseases such as rheumatoid arthritis, psoriasis or atopic dermatitis. But Socosur Chem. has worked hard to ensure that this molecule is available in Europe and internationally in a Biotech version for ocular and corneal surface pathologies with an inflammatory component, rather than using corticosteroids with their potential iatrogenic effect profiles.

Learn more

API Product Focus Erythromycin

Erythromycin prevents bacterial cells from multiplying and growing by interfering with the ability to make proteins, without affecting human cells. It is widely used to treat lung infections including pneumonia, skin problems including rosacea and acne, dental abscesses, as well as sexually transmitted infections.

Learn more

Top 3 European Leader in HBELs

More than 1,500 PDE and 1,000 OEL monographs have already been developed internally by the Tox by Design expert team, all signed by a European Registered Toxicologist (ERT).

Save Your Stability Program

Tox by Design offers a range of toxicological expertise to ensure the safety and quality of your pharmaceutical and biotech products.

Learn more

Product catalogs

Find & learn about our products. If you have any doubt, please contact us: we bring you solutions!

Latest news